GSK insider Waterhouse to head drugmaker HIV unit ViiV

Published On 2016-12-14 06:57 GMT   |   Update On 2016-12-14 06:57 GMT

GlaxoSmithKline said that Dominique Limet would step down at the end of March 2017 as head of the drugmaker's majority-owned HIV business ViiV Healthcare, to be replaced by GSK insider Deborah Waterhouse.


Water house, currently in charge of primary care within GSK's U.S. pharmaceuticals operation, will take over as ViiV chief executive at the same time as Emma Walmsley takes the helm of the wider GSK group.


Limet has led ViiV for the past seven years. In recent times sales have grown strongly on the back of new HIV medicines. Pfizer and Shionogi are minority shareholders in ViiV.

Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News